Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus

Nature Biotechnology
David C ChangAlexander A Khromykh

Abstract

DNA vaccines encoding replication-defective viruses are safer than inactivated or live attenuated viruses but may fail to stimulate an immune response sufficient for effective vaccination. We augment the protective capacity of a capsid-deleted flavivirus DNA vaccine by co-expressing the capsid protein from a separate promoter. In transfected cells, the capsid-deleted RNA transcript is replicated and translated to produce secreted virus-like particles lacking the nucleocapsid. This RNA is also packaged with the help of co-expressed capsid protein to form secreted single-round infectious particles (SRIPs) that deliver the RNA into neighboring cells. In SRIP-infected cells, the RNA is replicated again and produces additional virus-like particles, but in the absence of capsid RNA no SRIPs are formed and no further spread occurs. Compared with an otherwise identical construct that does not encode capsid, our vaccine offers better protection to mice after lethal West Nile virus infection. It also elicits virus-neutralizing antibodies in horses. This approach may enable vaccination against pathogenic flaviviruses other than West Nile virus.

References

Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·E RazM A Yankauckas
Nov 26, 1997·Journal of Virology·B D Lindenbach, C M Rice
Mar 9, 2000·Journal of Virology·A A KhromykhE G Westaway
Sep 6, 2001·Vaccine·T T LeA Suhrbier
Mar 22, 2002·Journal of Virology·Itaru AnrakuAlexander A Khromykh
Feb 1, 2003·The Journal of General Virology·S Susanna Twiddy, Edward C Holmes
Jun 5, 2003·International Journal for Parasitology·Konstantin V PugachevThomas P Monath
Aug 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Roy A HallAlexander A Khromykh
Feb 11, 2004·Proceedings of the National Academy of Sciences of the United States of America·Regina M KoflerChristian W Mandl
Jul 9, 2004·Veterinary Research·Javier Castillo-Olivares, James Wood
Jul 23, 2004·Expert Opinion on Biological Therapy·Roy A Hall, Alexander A Khromykh
Apr 7, 2005·Vaccine·Thomas P MonathJames H Strauss
Aug 29, 2006·Virology·Alexey SereginVladimir Yamshchikov

❮ Previous
Next ❯

Citations

May 10, 2008·Nature Biotechnology·Alan D T Barrett
Mar 3, 2012·Veterinary Research·Marina De FiletteNiek N Sanders
Apr 21, 2012·Emerging Infectious Diseases·Melinda J FrostPeter D Kirkland
Sep 13, 2013·International Journal of Environmental Research and Public Health·Arun V Iyer, Konstantin G Kousoulas
Dec 10, 2013·International Journal of Environmental Research and Public Health·Andriani MarkaGeorgios Eleftheriou
Oct 3, 2013·Viruses·Samantha Brandler, Frederic Tangy
Jan 1, 2014·Vaccines·Kenji OkudaMasaru Shimada
May 15, 2010·Journal of Biomedicine & Biotechnology·Penelope KorakaAlbert D M E Osterhaus
Nov 19, 2014·Future Microbiology·Sebastian Ulbert, Sofia E Magnusson
Aug 4, 2011·Journal of Invertebrate Pathology·Stefan W Metz, Gorben P Pijlman
Nov 15, 2008·The Journal of General Virology·Jody Hobson-PetersRoy A Hall
Apr 7, 2012·Biotechnology Advances·C A MartínezJ Rodríguez Talou
Nov 20, 2016·Annual Review of Animal Biosciences·Mia C Hikke, Gorben P Pijlman
Apr 3, 2014·Expert Review of Vaccines·Ian J Amanna, Mark K Slifka
Jan 18, 2020·Pathogens·Stephanea Sotcheff, Andrew Routh

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.